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OBJECTIVES: Genistein is known to influence reproductive system development through its binding affinity for
estrogen receptors. The present study aimed to further explore the effect of Genistein on the development of
the reproductive system of experimental rats.
METHODS: Eighteen post-weaning female Sprague Dawley rats were divided into the following groups: (i) a
control group that received vehicle (distilled water and Tween 80); (ii) a group treated with 10 mg/kg body
weight (BW) of Genistein (Gen 10); and (iii) a group treated with a higher dose of Genistein (Gen 100). The rats
were treated daily for three weeks from postnatal day 22 (P22) to P42. After the animals were sacrificed, blood
samples were collected, and the uteri and ovaries were harvested and subjected to light microscopy and
immunohistochemical study.
RESULTS: A reduction of the mean weekly BW gain and organ weights (uteri and ovaries) were observed in the
Gen 10 group compared to the control group; these findings were reversed in the Gen 100 group. Follicle
stimulating hormone and estrogen levels were increased in the Gen 10 group and reduced in the Gen 100
group. Luteinizing hormone was reduced in both groups of Genistein-treated animals, and there was a
significant difference between the Gen 10 and control groups (p,0.05). These findings were consistent with
increased atretic follicular count, a decreased number of corpus luteum and down-regulation of estrogen
receptors-a in the uterine tissues of the Genistein-treated animals compared to the control animals.
CONCLUSION: Post-weaning exposure to Genistein could affect the development of the reproductive system of
ovarian-intact experimental rats because of its action on the hypothalamic-pituitary-gonadal axis by regulating
hormones and estrogen receptors.
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& INTRODUCTION
The phytoestrogen Genistein belongs to a class of
isoflavones found in soybeans, which forms the main
dietary source of phytoestrogens for humans, cattle and
rodents (1-3). Despite many positive effects that have been
reported, questions are being raised regarding their role as
endocrine disrupting chemicals (4-6). Some adverse effects
have been observed in reproductive tract development and
differentiation (7-9).
The action of Genistein varies according to the types of
cells, the animal species and the treatment protocol,
including the dosage and period of exposure (10-13).
Genistein has been reported to exhibit estrogenic activity
by causing myometrial hypertrophy in Genistein-treated
rats (13). Its ability to suppress mammary cancer demon-
strates its anti-estrogenic activity (14-16). Both estrogenic
and anti-estrogenic actions of Genistein are associated with
the phenolic ring observed in its chemical structure. This
feature allows Genistein to bind to estrogen receptors (ER)
(12,17-20).
The two types of ER are ER-alpha (a) and ER-beta (b). Both
types of ER are found in brain, pituitary, and reproductive
tissues, including the uterus and ovary (4,21-23). Genistein
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has the ability to act as an exogenous ER ligand and to
compete with estrogen in the binding of ER (24). As a result,
the Genistein-receptor complex may produce an estrogenic
or anti-estrogenic effect on the reproductive organs. ER-a and
ER-b are primarily located in the uterus and ovary,
respectively; it is believed that they act as the main mediators
of estrogen action in these organs (4,19).
According to previous studies, Genistein exposure com-
monly begins during the neonatal period (9,13). However,
there are a few reports in which Genistein exposure started
during the post-weaning period. In humans, weaning is
defined as the period of transition from breastfeeding to other
dietary sources (25). Therefore, the chances of being exposed
to Genistein-containing food are higher at and after this age
(post-weaning). Because the post-weaning age coincides with
the critical stage of various neuroendocrine developments,
EDC exposure at this point may interrupt this process (26).
The main aim of the present study was to further explore the
effects of Genistein on the development of the reproductive
system in post-weaning Sprague Dawley (SD) rats.
& MATERIALS AND METHODS
Animals
Eighteen female SD rats at postnatal day 22 (P22) were
obtained from Animal Husbandry, University of Malaya
(UM). This study was approved by the Animal Care and
Committee (ACUC) of UM. SD rats were chosen because this
strain is relatively easy to handle and widely used in many
animal experiments worldwide (27,28). The rats were housed
individually in clean cages at room temperature (24-29 C˚)
with a normal 12-hour light-dark cycle. They had ad libitum
access to rat chow (Gold Coin Feedmills Pte. Ltd, Malaysia)
andwater. The rats were randomly divided into three groups
as follows: (i) the Control group received vehicle only (n= 6),
(ii) the Gen 10 group received Genistein at a dose of 10 mg/
kg body weight (BW) (n= 6), and (iii) the Gen 100 group
received Genistein at a dose of 100 mg/kg BW (n=6).
Chemicals and dosing
Genistein (Indofine Chemical Company, Hillsborough,
New Jersey, USA) was prepared in the following two doses:
low dose (10 mg/kg/day) and high dose (100 mg/kg/day).
Tween 80 (Sigma-Aldrich Chemical, St Louis, USA) was
used as the vehicle and diluted in distilled water (1:9 v/v).
All of the Genistein doses were chosen based on their
positive biological effects on female reproductive organs in
a preliminary study and other previous studies (13,29,30).
The hormonal enzyme-linked immunosorbent standard
assay (ELISA) kit was purchased from Cusabio (Newark,
Delaware, USA). For the immunohistochemistry (IHC)
study, the ER-a was identified using a rabbit polyclonal
antibody to ER-a (Abcam Inc., Cambridge, Massachusetts,
USA) at a dilution of 1:100.
Experimental procedures
Exposure to Genistein was initiated at P22, which was a
week prior to the beginning of the natural estrogen rise and
two weeks prior to the onset of puberty (around P35) (30).
The age of treatment in this study was based on previously
described research (30,31). Genistein was administered
daily for three weeks via oral gavage tube. The treatment
was given orally to mimic the common route of human
exposure. At P43, all rats were sacrificed, and blood samples
were collected for hormonal analysis. The uteri and ovaries
were harvested and processed for light microscopy and
IHC.
Hormonal assay
Blood samples were collected in EDTA tubes, centrifuged
at 1,000 rpm for 15 minutes, and stored at -20 C˚ until
hormonal analysis was conducted. Hormones including
estrogen, follicle stimulating hormone (FSH) and luteinizing
hormone (LH) were measured using an ELISA kit (Cusabio,
USA) according to the manufacturer’s guidelines. The
absorbance at 450 nm was determined using an ELISA
microtiter plate reader (BioTek, USA). To calculate the
hormone concentration, a standard curve was constructed
by plotting a graph of the absorbance of each reference
standard against its corresponding concentration.
Histological procedures
The uterine and ovarian tissues were excised and fixed in
10% formalin (Ajax Finechem, Taren Point, Australia).
Following these steps, the tissues were embedded in
paraffin (Paraplast, USA) and sectioned at 5-mm thickness.
Then, they were deparaffinized with xylene (BDH, England)
and hydrated in a series of different concentrations of
alcohol (HmbG Chemicals, Germany). Subsequently, the
slides were stained with hematoxylin and eosin (H & E),
mounted on glass slides and viewed under a light
microscope (Olympus CH-BI45-2). Representative uterine
tissue sections were chosen for the IHC procedure.
Immunohistochemistry
IHC was conducted to identify ER-a in the uterine tissues
using rabbit polyclonal antibody to ER-a. Tissue sections for
IHC were subjected to deparaffinization, hydration and
blocking of peroxidase activity. These steps were followed
by heating the sections in a microwave oven for antigen
retrieval using EDTA Tris saline (pH 9). The sections were
then incubated overnight at 4 C˚ with primary antibody [rabbit
polyclonal antibody to ER-a (Abcam Inc., USA)] diluted at
1:100, washed in Tris-saline (pH 7.6) (Abcam Inc., USA) and
incubated at room temperature for 30 minutes with ready-to-
use secondary antibody Dako REALTM EnVisionTM Detection
System (Abcam Inc., USA). Finally, the tissues were stained
with DAB, counter-stained with hematoxylin and viewed
under a light microscope (Olympus CH-BI45-2) for evaluation.
Analysis
For analysis of the ovary, 5-mm tissue sections were sampled
and examined under a light microscope (Olympus CH-BI45-
2). Morphometric analysis was performed on standard areas
of fields that were measured with grid lines using NIS-
Elements software (NIS-Elements Advanced Research, Nikon,
Japan). Fifty-three representative fields of ovarian tissues from
each group were randomly selected. Atretic follicles and
corpora lutea were identified, and follicular counts were
determined under x400 magnification. Atretic follicles were
characterized by the presence of degenerating oocytes and/or
apoptotic bodies among the granulosa cells (32,33). In contrast,
the corpora lutea were identified by the presence of large pale-
staining granulosa lutein cells (Figure 1) (34). Analysis of the
uterine wall (endometrium and myometrium) thickness was
also performed using the NIS-Elements software (NIS-
Elements Advanced Research, Nikon, Japan).
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For immunohistochemical analysis, the tissue sections
were observed under a light microscope for their staining
intensity. Representative sections of the ovarian and uterine
tissues were photographed with a Nikon Eclipse 80i upright
microscope equipped with a digital color camera controller
(DS-5Mc-U2).
The quantitative data were then analyzed using SPSS
(Version 20.0) statistical software. A one-way ANOVA was
used for the analysis. The results are presented as the
mean¡SEM. Differences were considered statistically sig-
nificant at p,0.05.
& RESULTS
Body Weight
BW gains were recorded weekly. Reduction of the mean
weekly BW gain was observed in the Gen 10 group
compared to the control group. In the Gen 100 group, the
mean BW gain was reduced during the first week but
recovered during subsequent weeks. However, the differ-
ence in BW gain between the Genistein-treated and control
groups was statistically insignificant (Figure 2).
Uterine and ovarian weight
Uterine weight was reduced following three-week treat-
ment in the Gen 10 group, but it was increased in the Gen
100 group compared to the control group. Similarly, the
ovarian weight was reduced in the Gen 10 group and
slightly increased in the Gen 100 group. Nevertheless, the
differences in the organ weights in the Genistein-treated rats
were not statistically significant compared to those of the
control group (Figure 3).
Hormonal assay
Following the three-week treatment, plasma FSH and
estrogen levels were increased in the Gen 10 group but were
decreased in the Gen 100 group compared to the control.
The plasma LH level was reduced in all of the Genistein-
treated groups. However, the reduction was only significant
for the Gen 10 group (p,0.05) (Table 1).
Light microscopy
Animals in the Gen 10 group exhibited a reduction in the
thickness of the endometrium and myometrium compared
to the control group. However, the opposite effect was
Figure 1 - Photomicrographs of the following types of ovarian follicles: (a) atretic and preantral follicles, (b) corpus luteum, (c) preantral
and antral follicles and (d) atretic and Graafian follicles. Note the disorganized layers of granulosa cells with apoptotic bodies (AP) in
the atretic follicles and the large pale-staining granulosa lutein cells of corpus luteum. A: antrum; O: oocyte; G: granulosa cells; T: theca
layer; F: fibroblasts. Scale bar = 50 mm.
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observed in the Gen 100 group. These findings were
consistent with the uterine weights of both Genistein-treated
groups (Table 2). Morphometric evaluation of the ovaries
showed an increase in the number of atretic follicles (AF)
with reduced counts of corpus luteum (CL) in both
Genistein-treated groups (Figures 4 and 5).
Immunohistochemistry
IHC was carried out to determine the effects of Genistein
on the regulation of ER-a in the uterus. Staining intensity for
ER-a in the uterine tissues was reduced in all Genistein-
treated groups compared with the control group; a marked
down-regulation was observed in the Gen 100 group
(Figure 6).
& DISCUSSION
In view of the adverse effects of phytoestrogens on
reproductive growth, concern over the intake of soymilk
and soy-based food has increased among researchers
worldwide (9,13). Genistein was chosen for this study
because it is the most abundant soy isoflavone found in
soybeans (35). Numerous studies have investigated the
effects of Genistein and its mechanism of action. However,
their findings have been inconsistent, which is likely
because of the different methods, subject characteristics,
study designs, dosages, or treatment lengths used (24,36).
In this study, the treatment in animal models was started
during the post-weaning period. This method corresponds
to the recommendation of the Malaysian National
Breastfeeding Policy that newborns be exclusively breastfed
for at least 6 months before being introduced to bottle-
feeding and a more solid diet (37). During recent times,
soymilk has been preferred for bottle feeding over cow’s
milk because of its known benefits or as a substitute in
children with lactose intolerance or allergies to cow’s milk
protein (5,6,15,38,39). Thus, more research must be con-
ducted to further understand the effects of soy isoflavones
(e.g., Genistein), which tend to be consumed at a higher
amount following weaning.
In the present study, the animals were treated with low-
dose and high-dose Genistein, which were expected to act
differently on ER. In a previous study, high-dose Genistein
was found to compete more effectively with endogenous
mammalian estrogens compared to a low-dose because of
the increased binding capacity of Genistein to ER (31). In
addition to ER, isoflavone Genistein may also exert an
estrogenic and/or anti-estrogenic effect on the hypothala-
mic-pituitary-gonadal (HPG) axis (35,40,41).
In the present study, animals with intact ovaries were
chosen to observe any changes in internal estrogen and the
complex HPG mechanism interaction secondary to
Genistein exposure. This method was used to represent
the effects of Genistein on humans with intact ovaries. Some
Figure 2 - Mean weekly BW gain among different groups. (Control) group given vehicle; (Gen 10) group treated with Genistein at a
dose of 10 mg/kg/day; (Gen 100) group treated with Genistein at a dose of 100 mg/kg/day; n= 6. The values are expressed as the
mean¡SEM.
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previous studies have used ovariectomized rats (13,29,42).
Ovariectomy was defined as the surgical removal of one or
both ovaries (43).
Preservation of the ovaries allowed the body to react to
Genistein via a feedback mechanism. The binding of
Genistein to ER may interfere with the release of gonado-
tropins, thus interrupting the feedback-regulating system of
the HPG axis (44). This process was observed in the Gen 100
group, in which poor BW gain was observed in the first
week of treatment compared to the control group; this
observation was followed by the recovery of BW in
subsequent weeks. These findings suggest the occurrence
of a feedback response to overcome this suppression.
However, the weekly BW gain in the Gen 10 group was
lower throughout the study period compared to the control
group. Nevertheless, the differences were not statistically
significant.
The effect of Genistein on BW gain in the present study
was consistent with the earlier findings of Kim et al. (2006)
(45). In that study, the BW of female ovariectomized mice
was significantly reduced following treatment with
Genistein at a dose of 1,500 mg/kg BW administered for
three weeks (45). Albeit the difference in the dosage used
was large, the action of Genistein in that study may have
occurred without any disruption to the level of internal
estrogen. In contrast, the present study used rats with intact
ovaries that could stimulate the body’s feedback response
secondary to high Genistein exposure (Gen 100).
Figure 3 - Mean uterine and ovarian weights after three weeks of treatment. (Control) group given vehicle; (Gen 10) group treated
with Genistein at a dose of 10 mg/kg/day; (Gen 100) group treated with Genistein at a dose of 100 mg/kg/day; n =6. The values are
expressed as the mean¡SEM.
Table 1 - Hormone levels following three weeks of
treatment. FSH, follicle stimulating hormone; LH,
luteinizing hormone. (Control) group given vehicle only;
(Gen 10) group treated with Genistein at a dose of 10 mg/
kg/day; (Gen 100) group treated with Genistein at a dose
of 100 mg/kg/day; n= 6.
Groups FSH (mIU/ml) LH (mIU/ml) Estrogen (pg/ml)
Control 35.13¡8.62 1.93¡0.66 43.64¡8.18
Gen 10 45.51¡13.13 0.37¡0.12* 63.74¡12.47
Gen 100 16.44¡2.71 0.75¡0.25 37.31¡4.65
*Significant difference compared to the control (p,0.05).
The values are expressed as the mean¡SEM.
Table 2 -Mean uterine wall thickness in different groups.
(Control) group given vehicle only; (Gen 10) group
treated with Genistein at a dose of 10 mg/kg/day; (Gen
100) group treated with Genistein at a dose of 100 mg/
kg/day; n= 6.
Groups Endometrium (mm) Myometrium (mm)
Control 259.81¡77.61 134.74¡34.52
Gen 10 181.01¡35.20 108.29¡24.09
Gen 100 267.60¡25.69 141.16¡10.45
The values are expressed as the mean¡SEM.
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In addition to BW, the effect of Genistein on uterine and
ovarian growth was also shown to be dose-dependent.
Following three weeks of treatment, uterine weights, uterine
wall thickness and ovarian weight were reduced in the Gen
10 group compared to the control group. These findings
were consistent with the poor BW gain in the same group.
However, opposite results were observed in the animals in
the Gen 100 group, which was also consistent with their
increased BW gain after three weeks of treatment. A similar
effect on uterine weight was observed by Diel et al. (2001)
following three days of administration of Genistein at a dose
of 100 mg/kg BW among ovariectomized rats (29).
However, the mechanism of action of Genistein in ovary-
intact rats should be different from that of ovariectomized
rats. Regarding the uterine wall thickness in the Gen 100
group, the observed effect was in agreement with the
previous study showing hypertrophy of the uterine wall in
rats treated with Genistein (13). In that study, the exposure
to Genistein was during the neonatal period (P1 to P5).
Nevertheless, the finding in the present study was statisti-
cally insignificant.
Apart from direct binding to ER in the uterine wall,
Genistein can also bind to the ER in the hypothalamus, which
has been found to reduce the production of gonadotrophin
releasing hormone (GnRH), thereby decreasing the secretion
of FSH and LH (30,40,42,44,46). A decreased FSH level can
affect follicular cell growth and subsequently reduce the
estrogen level (46). However, the levels of FSH and estrogens
in the animals in the Gen 10 group were found to be increased
following three weeks of treatment. In this group, it was
speculated that the FSH and estrogen levels were reduced
during the initial treatment phase. However, their low levels in
the circulation would have stimulated the HPG axis to
produce more GnRH. Thus, the level of FSH was increased
and stimulated the production of estrogen from the follicles
(47). However, in the Gen 100 group, there was persistent
suppression of FSH and estrogen production. Failure of the
HPG axis to overcome the suppression could be attributed to
the higher dose of Genistein compared to the Gen 10 group.
LH was reduced in both Genistein-treated groups
compared to the control group. The reduction of the LH
level was consistent with the increased number of AF and
reduced count of CL in the Genistein-treated animals, with
significant results seen in the Gen 10 group (p,0.05). The
LH surge is necessary for ovulation; thus, lower levels of LH
may explain the lack of ovulation seen in both Genistein-
treated groups (41). This finding is in agreement with a
previous study showing many AF with absent CL in some
Genistein-treated rats (13). Those rats failed to become
pregnant after mating with an untreated male, which
Figure 4 - Bar chart of the ovarian follicular count among different groups. (Control) group given vehicle; (Gen 10) group treated with
Genistein at a dose of 10 mg/kg/day; (Gen 100) group treated with Genistein at a dose of 100 mg/kg/day; n=6. AF, atretic follicle; CL,
corpus luteum. *Significant difference compared with the control (p,0.05). The values are expressed as the mean¡SEM.
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suggests that there may be a risk of infertility that is
secondary to Genistein exposure (13).
Interestingly, contradictory results were observed in the
Gen 100 group; FSH and estrogen levels were reduced, but
the uterine weight, uterine wall thickness and ovarian
weight were increased. Such findings were most likely
caused by the other factors involved in the ovarian
regulation and uterine growth that were not included in
this study. In addition to GnRH, the binding of Genistein to
ER in the hypothalamus may have affected the production
of growth hormone (GH) and growth factors (GF).
Furthermore, a central estrogen-like effect of Genistein
was found to stimulate GH secretion in ewes (48). In
another study, dietary Genistein affected the hypothalamic-
pituitary axis and enhanced the release of GnRh and GH
(44). Therefore, it is speculated that the Gen 100 group
might experience similar effects as those found in previous
studies, namely increased uterine weight, wall thickness
and ovarian weight. However, it was found that GH in the
Gen 10 group was decreased. Thus, the organ weights and
wall thickness were reduced despite the increase in FSH and
estrogen levels.
Other than GH, GF such as transforming GF alpha (TGF-
a), epidermal GF (EGF), insulin-like GF-I (IGF-I), and
fibroblast GF (FGF) are known to undergo changes at
puberty and during follicular development (26,49,50). Ma YJ
et al. (1992) have shown that GF suppression can delay the
onset of puberty (51). Moreover, endometrial growth has
been shown to involve GF and hormone signaling (52).
Based on these previous findings, we speculated that the
levels of GH and GF in the present study would be affected
in both Genistein-treated groups (53).
Despite varieties in growth, morphological and hormonal
assay findings, both Genistein-treated groups exhibited
down-regulation of ER-a in uterine tissues, with greater
suppression observed in the Gen 100 group. This finding is
consistent with the previous study by Cotroneo et al. (2001)
despite the different method used (42). In their study,
Genistein was administered at a dose of 500 mg/kg BW to
prepubertal ovariectomized rats for three days. Down-
regulation of ER-a in the present study may have occurred
secondary to proteolysis of the receptors or direct suppres-
sion of the gonadal tissues following continuous Genistein
exposure (42,44,46,47). Detection of ER-a in the uterus of the
present study was performed using IHC as commonly used
by previous researchers (4,22). ER-a was the only receptor
evaluated in the present study because of its limited cost. In
addition, ER-a is the predominant receptor in the uterus,
which suggests its main role in mediating the effects of
estrogen on the uterine tissues (4,54).
The present study was conducted to determine the
consequences of post-weaning exposure to different
dosages of Genistein. Low (10 mg/kg) and high (100 mg/
kg) doses of Genistein showed various effects on pubertal
Figure 5 - Photomicrographs of ovaries stained with H & E. (a) Control group given vehicle only; (b) Group treated with Genistein at a
dose of 10 mg/kg/day (Gen 10); (c) Group treated with Genistein at a dose of 100 mg/kg/day (Gen 100); n =6. Note: The number of CL is
highest in the control group. Scale bar= 50 mm.
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reproductive growth. This is attributed to the ability of
Genistein to act on multiple locations, such as the
hypothalamus, pituitary and gonads, which leads to a
complex mechanism of action (30). However, poor ovarian
follicular growth and ER-a down-regulation in the uterus
were observed in both groups, which suggests the anti-
estrogenic (antagonistic) effect of Genistein. Nevertheless,
this hypothesis requires further study for confirmation.
To date, studies have shown that Genistein interferes with
many biochemical pathways and that its mode of action in
the living cell is complex and multidirectional (46). The high
sensitivity of uterine tissue to estrogens makes the female
reproductive tract vulnerable to environmental compounds
with estrogen-like features. Thus, as clinicians and research-
ers, we should consider the possibility that there may often
be an environmental basis for disorders related to the
female reproductive system (55). Therefore, further studies
are required to determine the guidelines for safe consumer
dosage in view of increasing Genistein consumption via
soy-based formula milk in infants and over-the-counter
supplements in adults.
& ACKNOWLEDGMENTS
This research was supported by a postgraduate research grant and a
research university grant from the University of Malaya. We would like to
acknowledge all of the support staff of the Anatomy Department for their
help throughout the study.
& AUTHOR CONTRIBUTIONS
Zin SR was the lead researcher of the project and also contributed to
analyzing the results and writing the manuscript. Kassim NM planned the
study, guided the lead researcher for the project and contributed to the
planning, design, manuscript writing, editing and journal selection. Omar
SZ co-supervised the project and contributed to the study design and
analysis of the results. Khan NL contributed to the analysis of the results (as
an expert in morphometric analysis) and manuscript writing. Musameh NI
Figure 6 - Photomicrographs of uterine tissues stained with antibody to ER-a. (a) Control, (b) Gen 10, (c) Gen 100, (d) Negative control.
GL: endometrial gland; E: epithelium; BV: blood vessel. *Negative controls were performed by omitting the primary and secondary
antibody. Scale bar = 50 mm.
Phytoestrogen on reproductive development
Zin SR et al.
CLINICS 2013;68(2):253-262
260
performed the study as the co-researcher and also contributed to the
manuscript writing. Das S contributed to editing and writing the
manuscript.
& REFERENCES
1. Reinli K, Block G. Phytoestrogen content of foods—a compendium of
literature values. Nutr Cancer. 1996;26(2):123-48. Epub 1996/01/01,
http://dx.doi.org/10.1080/01635589609514470.
2. Cornwell T, Cohick W, Raskin I. Dietary phytoestrogens and health.
Phytochemistry. 2004;65(8):995-1016. Epub 2004/04/28, http://dx.doi.
org/10.1016/j.phytochem.2004.03.005.
3. Cederroth CR, Nef S. Soy, phytoestrogens and metabolism: A review.
Mol Cell Endocrinol. 2009;304(1-2):30-42. Epub 2009/05/13, http://dx.
doi.org/10.1016/j.mce.2009.02.027.
4. Pelletier G, El-Alfy M. Immunocytochemical localization of estrogen
receptors alpha and beta in the human reproductive organs. J Clin
Endocrinol Metab. 2000;85(12):4835-40. Epub 2001/01/03, http://dx.doi.
org/10.1210/jc.85.12.4835.
5. Tham DM, Gardner CD, Haskell WL. Clinical review 97: Potential health
benefits of dietary phytoestrogens: a review of the clinical, epidemiological,
and mechanistic evidence. J Clin Endocrinol Metab. 1998;83(7):2223-35.
Epub 1998/07/14, http://dx.doi.org/10.1210/jc.83.7.2223.
6. Adlercreutz H. Phytoestrogens. State of the art. Environ Toxicol
Pharmacol. 1999;7(3):201-7. Epub 1999/07/01, http://dx.doi.org/10.
1016/S1382-6689(99)00014-9.
7. Kallela K, Heinonen K, Saloniemi H. Plant oestrogens; the cause of
decreased fertility in cows. A case report. Nord Vet Med. 1984;36(3-
4):124-9. Epub 1984/03/01.
8. Setchell KD, Gosselin SJ, Welsh MB, Johnston JO, Balistreri WF, Kramer
LW, et al. Dietary estrogens—a probable cause of infertility and liver
disease in captive cheetahs. Gastroenterology. 1987;93(2):225-33. Epub
1987/08/01.
9. Jefferson WN, Couse JF, Padilla-Banks E, Korach KS, Newbold RR.
Neonatal exposure to genistein induces estrogen receptor (ER)alpha
expression and multioocyte follicles in the maturing mouse ovary:
evidence for ERbeta-mediated and nonestrogenic actions. Biol Reprod.
2002;67(4):1285-96. Epub 2002/09/26, http://dx.doi.org/10.1095/
biolreprod67.4.1285.
10. Park OJ. Comparison of estrogen and genistein in their antigenotoxic
effects, apoptosis and signal transduction protein expression patterns.
Biofactors. 2004;21(1-4):379-82. Epub 2005/01/05, http://dx.doi.org/10.
1002/biof.552210173.
11. Miyazaki K. Novel approach for evaluation of estrogenic and anti-
estrogenic activities of genistein and daidzein using B16 melanoma cells
and dendricity assay. Pigment Cell Res. 2004;17(4):407-12. Epub 2004/
07/15, http://dx.doi.org/10.1111/j.1600-0749.2004.00167.x.
12. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens
and their human metabolites show distinct agonistic and antagonistic
properties on estrogen receptor alpha (ERalpha) and ERbeta in human
cells. Toxicol Sci. 2004;80(1):14-25. Epub 2004/04/16, http://dx.doi.org/
10.1093/toxsci/kfh147.
13. Nagao T, Yoshimura S, Saito Y, Nakagomi M, Usumi K, Ono H.
Reproductive effects in male and female rats of neonatal exposure to
genistein. Reprod Toxicol. 2001;15(4):399-411. Epub 2001/08/08, http://
dx.doi.org/10.1016/S0890-6238(01)00141-1.
14. Murrill WB, Brown NM, Zhang JX, Manzolillo PA, Barnes S,
Lamartiniere CA. Prepubertal genistein exposure suppresses mammary
cancer and enhances gland differentiation in rats. Carcinogenesis.
1996;17(7):1451-7. Epub 1996/07/01, http://dx.doi.org/10.1093/carcin/
17.7.1451.
15. Hilakivi-Clarke L, Onojafe I, Raygada M, Cho E, Skaar T, Russo I, et al.
Prepubertal exposure to zearalenone or genistein reduces mammary
tumorigenesis. Br J Cancer. 1999;80(11):1682-8. Epub 1999/09/01, http://
dx.doi.org/10.1038/sj.bjc.6690584.
16. Warri A, Saarinen NM, Makela S, Hilakivi-Clarke L. The role of early life
genistein exposures in modifying breast cancer risk. Br J Cancer.
2008;98(9):1485-93. Epub 2008/04/09, http://dx.doi.org/10.1038/sj.bjc.
6604321.
17. Makela S, Davis VL, Tally WC, Korkman J, Salo L, Vihko R, et al. Dietary
Estrogens Act through Estrogen Receptor-Mediated Processes and Show
No Antiestrogenicity in Cultured Breast Cancer Cells. Environ Health
Perspect. 1994;102(6-7):572-8. Epub 1994/06/01, http://dx.doi.org/10.
1289/ehp.94102572.
18. Hunter DS, Hodges LC, Vonier PM, Fuchs-Young R, Gottardis MM,
Walker CL. Estrogen receptor activation via activation function 2
predicts agonism of xenoestrogens in normal and neoplastic cells of
the uterine myometrium. Cancer Res. 1999;59(13):3090-9. Epub 1999/07/
09.
19. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag
PT, et al. Interaction of estrogenic chemicals and phytoestrogens with
estrogen receptor beta. Endocrinology. 1998;139(10):4252-63. Epub 1998/
09/29, http://dx.doi.org/10.1210/en.139.10.4252.
20. le Maire A, Bourguet W, Balaguer P. A structural view of nuclear hormone
receptor: endocrine disruptor interactions. Cell Mol Life Sci.
2010;67(8):1219-37. Epub 2010/01/12, http://dx.doi.org/10.1007/s00018-
009-0249-2.
21. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta
in human tissues. J Mol Endocrinol. 2000;24(1):145-55. Epub 2000/02/05,
http://dx.doi.org/10.1677/jme.0.0240145.
22. Hiroi H, Inoue S, Watanabe T, Goto W, Orimo A, Momoeda M, et al.
Differential immunolocalization of estrogen receptor alpha and beta in
rat ovary and uterus. J Mol Endocrinol. 1999;22(1):37-44. Epub 1999/01/
30, http://dx.doi.org/10.1677/jme.0.0220037.
23. Sar M, Welsch F. Differential expression of estrogen receptor-beta and
estrogen receptor-alpha in the rat ovary. Endocrinology. 1999;140(2):963-
71. Epub 1999/02/02, http://dx.doi.org/10.1210/en.140.2.963.
24. Setchell KD. Soy isoflavones—benefits and risks from nature’s selective
estrogen receptor modulators (SERMs). J Am Coll Nutr. 2001;20(5
Suppl):354S-62S; discussion 81S-83S. Epub 2001/10/18.
25. Jonas WB. Mosby’s dictionary of complementary and alternative
medicine. St. Louis, MO: Mosby; 2005. 519 p.
26. Goldman JM, Laws SC, Balchak SK, Cooper RL, Kavlock RJ. Endocrine-
disrupting chemicals: prepubertal exposures and effects on sexual
maturation and thyroid activity in the female rat. A focus on the
EDSTAC recommendations. Crit Rev Toxicol. 2000;30(2):135-96. Epub
2000/04/12, http://dx.doi.org/10.1080/10408440091159185.
27. Gray LE, Wilson V, Noriega N, Lambright C, Furr J, Stoker TE, et al. Use
of the laboratory rat as a model in endocrine disruptor screening and
testing. Ilar Journal. 2004;45(4):425-37.
28. Ghadially FN. Ultrastructural pathology of the cell : a text and atlas of
physiological and pathological alterations in cell fine structure. London;
Boston: Butterworths; 1975. xvi, 543 p.
29. Diel P, Smolnikar K, Schulz T, Laudenbach-Leschowski U, Michna H,
Vollmer G. Phytoestrogens and carcinogenesis-differential effects of
genistein in experimental models of normal and malignant rat
endometrium. Hum Reprod. 2001;16(5):997-1006. Epub 2001/05/02,
http://dx.doi.org/10.1093/humrep/16.5.997.
30. Rasier G, Toppari J, Parent AS, Bourguignon JP. Female sexual
maturation and reproduction after prepubertal exposure to estrogens
and endocrine disrupting chemicals: a review of rodent and human data.
Mol Cell Endocrinol. 2006;254-255:187-201. Epub 2006/05/25, http://dx.
doi.org/10.1016/j.mce.2006.04.002.
31. U.S.EPA. Endocrine Disruptor Screening Program. 2005.
32. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and
follicular renewal in the postnatal mammalian ovary. Nature.
2004;428(6979):145-50. Epub 2004/03/12, http://dx.doi.org/10.1038/
nature02316.
33. Gaytan F, Morales C, Bellido C, Aguilar E, Sanchez-Criado JE. Ovarian
follicle macrophages: is follicular atresia in the immature rat a
macrophage-mediated event? Biol Reprod. 1998;58(1):52-9. Epub 1998/
02/24, http://dx.doi.org/10.1095/biolreprod58.1.52.
34. Zhang S-x. An atlas of histology. New York: Springer; 1999. xvii, 426 p.,
309 color plates p.
35. Albulescu M, Popovici M. Isoflavones-biochemistry, pharmacology and
therapeutic use. Revue Roumaine de Chimie. 2007;52(6):537-50.
36. Lamartiniere CA, Zhang JX, Cotroneo MS. Genistein studies in rats:
potential for breast cancer prevention and reproductive and develop-
mental toxicity. Am J Clin Nutr. 1998;68(6 Suppl):1400S-5S. Epub 1998/
12/16.
37. Fatimah S, Jr., Siti Saadiah HN, Tahir A, Hussain Imam MI, Ahmad
Faudzi Y. Breastfeeding in Malaysia: Results of the Third National
Health and Morbidity Survey (NHMS III) 2006. Malays J Nutr.
2010;16(2):195-206. Epub 2010/08/01.
38. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P,
Winston M. Soy protein, isoflavones, and cardiovascular health: a
summary of a statement for professionals from the american heart
association nutrition committee. Arterioscler Thromb Vasc Biol.
2006;26(8):1689-92. Epub 2006/07/22, http://dx.doi.org/10.1161/01.
ATV.0000227471.00284.ef.
39. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Isoflavone content of
infant formulas and the metabolic fate of these phytoestrogens in early
life. Am J Clin Nutr. 1998;68(6 Suppl):1453S-61S. Epub 1998/12/16.
40. Cassidy A, Bingham S, Setchell K. Biological effects of isoflavones in
young women: importance of the chemical composition of soyabean
products. Br J Nutr. 1995;74(4):587-601. Epub 1995/10/01.
41. Jefferson WN, Padilla-Banks E, Newbold RR. Disruption of the
developing female reproductive system by phytoestrogens: genistein as
an example. Mol Nutr Food Res. 2007;51(7):832-44. Epub 2007/07/03,
http://dx.doi.org/10.1002/mnfr.200600258.
42. Cotroneo MS, Wang J, Eltoum IA, Lamartiniere CA. Sex steroid receptor
regulation by genistein in the prepubertal rat uterus. Mol Cell
Endocrinol. 2001;173(1-2):135-45. Epub 2001/02/27, http://dx.doi.org/
10.1016/S0303-7207(00)00405-6.
43. Miller BF, Keane CB. Miller-Keane Encyclopedia & dictionary of
medicine, nursing & allied health. 6th ed. Philadelphia: Saunders;
1997. xxxii, 1960 p.
CLINICS 2013;68(2):253-262 Phytoestrogen on reproductive development
Zin SR et al.
261
44. Ren MQ, Kuhn G, Wegner J, Chen J. Isoflavones, substances with multi-
biological and clinical properties. Eur J Nutr. 2001;40(4):135-46. Epub
2002/03/22.
45. Kim HK, Nelson-Dooley C, Della-Fera MA, Yang JY, Zhang W, Duan J,
et al. Genistein decreases food intake, body weight, and fat pad weight
and causes adipose tissue apoptosis in ovariectomized female mice.
J Nutr. 2006;136(2):409-14. Epub 2006/01/21.
46. Polkowski K, Mazurek AP. Biological properties of genistein. A review
of in vitro and in vivo data. Acta Pol Pharm. 2000;57(2):135-55. Epub
2000/08/10.
47. Schoeters G, Den Hond E, Dhooge W, van Larebeke N, Leijs M.
Endocrine disruptors and abnormalities of pubertal development. Basic
Clin Pharmacol Toxicol. 2008;102(2):168-75. Epub 2008/01/30, http://
dx.doi.org/10.1111/j.1742-7843.2007.00180.x.
48. Misztal T, Wankowska M, Gorski K, Romanowicz K. Central estrogen-
like effect of genistein on growth hormone secretion in the ewe. Acta
Neurobiol Exp (Wars). 2007;67(4):411-9. Epub 2008/03/07.
49. Lucy MC. Regulation of ovarian follicular growth by somatotropin and
insulin-like growth factors in cattle. J Dairy Sci. 2000;83(7):1635-47. Epub
2000/07/25, http://dx.doi.org/10.3168/jds.S0022-0302(00)75032-6.
50. Giudice LC. Insulin-like growth factors and ovarian follicular develop-
ment. Endocr Rev. 1992;13(4):641-69. Epub 1992/11/01.
51. Ma YJ, Junier MP, Costa ME, Ojeda SR. Transforming growth factor-alpha
gene expression in the hypothalamus is developmentally regulated and
linked to sexual maturation. Neuron. 1992;9(4):657-70. Epub 1992/10/01.
52. Gargett CE, Chan RW, Schwab KE. Hormone and growth factor
signaling in endometrial renewal: role of stem/progenitor cells. Mol
Cell Endocrinol. 2008;288(1-2):22-9. Epub 2008/04/12, http://dx.doi.
org/10.1016/j.mce.2008.02.026.
53. Brown NM, Lamartiniere CA. Genistein regulation of transforming
growth factor-alpha, epidermal growth factor (EGF), and EGF receptor
expression in the rat uterus and vagina. Cell Growth Differ.
2000;11(5):255-60. Epub 2000/06/14.
54. Pelletier G, Labrie C, Labrie F. Localization of oestrogen receptor alpha,
oestrogen receptor beta and androgen receptors in the rat reproductive
organs. J Endocrinol. 2000;165(2):359-70. Epub 2000/05/16, http://dx.
doi.org/10.1677/joe.0.1650359.
55. McLachlan JA, Simpson E, Martin M. Endocrine disrupters and female
reproductive health. Best Pract Res Clin Endocrinol Metab. 2006;20(1):63-
75. Epub 2006/03/09, http://dx.doi.org/10.1016/j.beem.2005.09.009.
Phytoestrogen on reproductive development
Zin SR et al.
CLINICS 2013;68(2):253-262
262
